Compare LSAK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSAK | VNDA |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.0M | 441.5M |
| IPO Year | N/A | 2006 |
| Metric | LSAK | VNDA |
|---|---|---|
| Price | $4.64 | $8.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 77.5K | ★ 2.7M |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $677,582,000.00 | $212,074,000.00 |
| Revenue This Year | $11.97 | $12.01 |
| Revenue Next Year | $9.14 | $24.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.48 | 11.12 |
| 52 Week Low | $3.39 | $3.81 |
| 52 Week High | $5.20 | $9.60 |
| Indicator | LSAK | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 61.30 |
| Support Level | $4.47 | $7.14 |
| Resistance Level | $4.72 | $7.82 |
| Average True Range (ATR) | 0.23 | 0.44 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 51.43 | 62.09 |
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates three reportable segments: Merchant, Consumer and Enterprise. Merchant, which focuses on both formal and informal sector merchants. Consumer, which focuses on individuals who have historically been excluded from traditional financial services and to whom it offers transactional accounts (banking), insurance, lending (short-term loans), payments solutions and various value-added services; and Enterprise, which comprises large-scale corporate and government organizations, including but not limited to banks, mobile network operators (MNOs) and municipalities, and, through Recharger, landlords utilizing Recharger's prepaid electricity metering solution.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.